Drug profile

The FDA adverse-event record for Sometribove Zinc Suspension

64 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Sometribove Zinc Suspension. See the species affected, top reactions, and outcomes below.

64
adverse-event reports
3.1%
death-coded share
Cattle
most-reported species
12
INEFFECTIVE, PRODUCTION (MILK) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
64
Total Reports
2
Deaths Reported
3.1%
Death Rate

Active Ingredients

Sometribove Zinc Suspension

Administration Routes

UnknownSubcutaneousOralIntradermal

Species Affected

Cattle 55
Human 5
Unknown 4

Most Affected Breeds

Holstein-Friesian also known as Holstein 39
Unknown 9
Jersey 7
Cattle (other) 7
Holstein-Friesian - Swedish 1
Cattle (unknown) 1

Most Reported Reactions

INEFFECTIVE, PRODUCTION (MILK) 12
Alteration of milk quality 10
Reduced conception rate 6
Milk production decrease 6
Mastitis NOS 5
Injection site swelling 5
Milk production increase 4
Injection site abscess 3
Death 3
Mammary gland disorder NOS 3
Female reproductive tract disorder NOS 2
Lack of efficacy - NOS 2

Outcome Breakdown

Outcome Unknown
35 (56.5%)
Recovered with Sequela
12 (19.4%)
Recovered/Normal
11 (17.7%)
Ongoing
2 (3.2%)
Died
2 (3.2%)

Sometribove Zinc Suspension Adverse Event Insights

64 reports name Sometribove Zinc Suspension; 2 recorded a death outcome (3.1% of reported events, not a population-level mortality rate). Active ingredient: Sometribove Zinc Suspension. Administration routes: Unknown, Subcutaneous, Oral, Intradermal.

By species: Cattle (55 reports), Human (5 reports), Unknown (4 reports). By breed: Holstein-Friesian also known as Holstein (39), Unknown (9), Jersey (7).

Leading clinical signs: INEFFECTIVE, PRODUCTION (MILK) (12), Alteration of milk quality (10), Reduced conception rate (6), Milk production decrease (6). Outcome, 62 coded reports: Outcome Unknown leads at 56.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.